<DOC>
	<DOCNO>NCT00006232</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know combination chemotherapy regimen effective multiple myeloma . PURPOSE : This randomized phase III trial compare two combination chemotherapy regimens see well work treat patient stage II stage III multiple myeloma .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Patients With Stage II Stage III Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : - Compare partial complete response rate patient multiple myeloma treat induction therapy comprise idarubicin dexamethasone v vincristine , doxorubicin , dexamethasone . - Compare disease progression , time achieve maximal response , duration response patient treat 2 regimen . - Compare quality life patient treat 2 regimen . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral idarubicin oral dexamethasone daily day 1-4 . Treatment continue every 3 week 4 course absence disease progression unacceptable toxicity . Patients also receive oral dexamethasone daily day 8-11 course 1 . - Arm II : Patients receive oral dexamethasone daily , doxorubicin IV continuously , vincristine IV continuously day 1-4 . Courses repeat arm I . Patients receive additional dexamethasone arm I . Patients without maximal response completion course 4 may receive 2 additional course . Quality life assess baseline prior study course . Patients follow survival . PROJECTED ACCRUAL : A total 200 patient ( 100 per arm ) accrue study within 2 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis stage II III multiple myeloma No prior therapy except local radiotherapy bone lesions No indolent multiple myeloma No monoclonal gammopathy unknown significance PATIENT CHARACTERISTICS : Age : 75 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.34 mg/dL Renal : No end stage renal failure ( creatinine great 5.65 mg/dL rehydration ) No requirement dialysis Other : No medical condition would preclude intensive treatment Not pregnant nursing Fertile patient must use effective contraception No prior malignancy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy See Disease Characteristics Radiotherapy Concurrent local radiotherapy allow painful lesion lesion appear likely lead imminent fracture Surgery See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>